Current Report Filing (8-k)
28 April 2021 - 2:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549 FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 22, 2021
GENEREX
BIOTECHNOLOGY CORPORATION
(Exact
of registrant as specified in its charter)
DELAWARE
|
000-29169
|
98-0178636
|
State
or other jurisdiction of incorporation
|
Commission
File Number
|
IRS
Employer Identification No.
|
10102
USA Today Way, Miramar, Florida 33025 (Address of principal executive offices) (Zip Code)
(416)
364-2551
(Registrant’s
telephone number, including area code) (Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Item
8.01 Other Events.
In
connection with its partnership with the National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease
Control and Prevention, Beijing Youfeng International Consulting Co., Ltd and Beijing Guoxin Haixiang Equity Investment Partnership,
Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”)
received $2,000,000 on April 22, 2021, from Beijing Youfeng Biological Technology Co. LTD (“YouFeng”) to provide necessary
materials to YouFeng for its IND submissions to the Chinese National Medical Products Administration (China’s equivalent
to the US Food & Drug Administration) to obtain approval in China for Generex’s Ii-Key SARS-CoV-2 coronavirus peptide
vaccine.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
None
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
April 27, 2021
GENEREX
BIOTECHNOLOGY CORPORATION
/s/Joseph
Moscato
By:
Joseph Moscato, CEO, President
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Aug 2023 to Aug 2024